NANOGNOSTICS
Quantum Dot-Based Highly Sensitive Immunoassays for Multiplexed Diagnostics of Alzheimer's Disease
| Coordinatore | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.nanognostics.org/ |
| Totale costo | 5˙281˙158 € |
| EC contributo | 4˙037˙064 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-10-01 - 2013-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | coordinator | 448˙725.00 |
| 2 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 578˙800.00 |
| 3 |
EDINBURGH INSTRUMENTS LTD
Organization address
address: Bain Square 2 contact info |
UK (LIVINGSTON) | participant | 539˙400.00 |
| 4 |
THE HEBREW UNIVERSITY OF JERUSALEM.
Organization address
address: GIVAT RAM CAMPUS contact info |
IL (JERUSALEM) | participant | 515˙100.00 |
| 5 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 488˙700.00 |
| 6 |
PHILIPPS UNIVERSITAET MARBURG
Organization address
address: Biegenstrasse 10 contact info |
DE (MARBURG) | participant | 453˙500.00 |
| 7 |
TURUN YLIOPISTO
Organization address
address: YLIOPISTONMAKI contact info |
FI (TURUN YLIOPISTO) | participant | 373˙599.80 |
| 8 |
UNIVERSITAET POTSDAM
Organization address
address: AM NEUEN PALAIS 10 contact info |
DE (POTSDAM) | participant | 364˙800.00 |
| 9 |
UNIVERSITE PARIS-SUD
Organization address
address: RUE GEORGES CLEMENCEAU 15 contact info |
FR (ORSAY) | participant | 274˙439.20 |
| 10 |
Arctic Photonics Oy
Organization address
address: TILLINMAANPUISTO 3A contact info |
FI (ESPOO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'6.1 million people currently live with a form of dementia in the European Union with an addition of 1.4 million new cases every year. Combination of psychological testing, brain-imaging and exclusion of other neurological disorders makes the diagnosis of Alzheimer’s disease complicated and time consuming (taking up to 20 months). A rapid, sensitive and specific immunoassay for protein markers inside blood would largely improve early diagnosis and lead to a better treatment of dementia. Homogeneous assays based on FRET from one dye labeled specific antibody (AB1) to another (AB2) within an “AB1-biomarker-AB2” immune complex are an ideal basis to meet these diagnostic requirements. As the detection of several protein markers is obligatory for a highly sensitive and specific diagnosis an optical multiplexing approach with dyes of different colors is a smart solution. Semiconductor quantum dots (QDs) are the ideal candidates due to their size-dependent absorption and emission wavelengths. Moreover, they possess unique photophysical properties that overcome conventional fluorescence dyes. In combination with lanthanide complexes (LCs), that display long luminescence lifetimes and well separated emission bands, QDs render a powerful multiplexing tool for highly sensitive diagnostics even for large immune complexes. FRET applications using QDs are to date restricted to academic research and a profound understanding of QD-based FRET is not available. For a comprehensive analysis the use of LCs is mandatory, because they are the only known donors for efficient FRET to QD acceptors. NANOGNOSTICS strives for a profound understanding of QD-based FRET, the synthetic creation of highly efficient QD immune sensors for detection of several Alzheimer-specific protein markers and the development of a modular high-throughput-screening immuno analyzer for the integration of QD-based multiplexing immunoassays into early diagnosis for improved patient outcome in dementia therapy.'
Introduzione (Teaser)
Millions of people worldwide are living with some kind of dementia. Tools offering prompt and accurate disease diagnosis could significantly postpone disease progression or even treat major symptoms.